Ahmad Alkaddour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ahmad Alkaddour has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Wahab Hritani
University of Florida-Jacksonville, Jacksonville, FL 32209, USA
1 shared publication - Apryl Cronley
Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA
1 shared publication Camille McGaw
Division of Gastroenterology, University of Florida/Jacksonville, Jacksonville, FL, USA
1 shared publicationCarlos Palacio
Department of Medicine, University of Florida/Jacksonville, Jacksonville, FL, USA
1 shared publication- Carlos Palacio
University of Florida College of Medicine, Jacksonville, USA
1 shared publication Jeff House
University of Florida-Jacksonville, Jacksonville, FL 32209, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (4) , 71
Pharmacy Intervention Matters: Improving the Quality of Care of Helicobacter pylori Treatment
Objectives: Helicobacter pylori (HP) infection has an estimated prevalence of ~4.4 billion individuals worldwide. Clinical manifestations range from asymptomatic to mucosa-associated lymphoid tissue lymphoma. Effective eradication depends on both appropriate treatment selection and patient adherence. The study aims were compare HP eradication rates, antibiotic regimen selection and confirmation testing between patients managed by a clinical pharmacist versus standard care. Methods: A retrospective review of adults diagnosed and treated for HP was performed between March 2019 and November 2021. Patients were divided into two sequential cohorts: a pre-pharmacy group receiving standard care, and a pharmacist intervention group in which a clinical pharmacist managed treatment and documented HP eradication. Data analyzed included multiple demographic and clinical factors. Eradication was assessed by intention-to-treat (ITT) and per-protocol analysis with proportions compared using chi-square or Fisher’s Exact Test for low cell counts. Results: A total of 134 patients were diagnosed and treated for HP during the study period: 38 in the pre-pharmacy group and 96 in the pharmacist intervention group. In ITT analysis, successful eradication did not differ significantly between groups. Per-protocol analysis revealed significantly higher eradication in the pharmacist group. Antibiotic regimens overall differed between the cohorts with less use of clarithromycin-based triple therapy and greater use of non-bismuth quadruple (concomitant) therapy in the pharmacist group. Other evaluated items were not significantly different between groups. Conclusions: Clinical pharmacist HP care management was associated with more consistent, guideline-concordant antibiotic regimen selection and higher eradication rates among patients completing confirmatory testing. These findings support a role for pharmacist-led HP care for process improvement including regimen selection and eradication testing; prospective studies with systematic confirmatory testing are needed to determine the model’s effect on eradication itself.
- 1 November 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (4) , 71
Open AccessPharmacy Intervention Matters: Improving the Quality of Care of Helicobacter pylori Treatment
Objectives: Helicobacter pylori (HP) infection has an estimated prevalence of ~4.4 billion individuals worldwide. Clinical manifestations range from asymptomatic to mucosa-associated lymphoid tissue lymphoma. Effective eradication depends on both appropriate treatment selection and patient adherence. The study aims were compare HP eradication rates, antibiotic regimen selection and confirmation testing between patients managed by a clinical pharmacist versus standard care. Methods: A retrospective review of adults diagnosed and treated for HP was performed between March 2019 and November 2021. Patients were divided into two sequential cohorts: a pre-pharmacy group receiving standard care, and a pharmacist intervention group in which a clinical pharmacist managed treatment and documented HP eradication. Data analyzed included multiple demographic and clinical factors. Eradication was assessed by intention-to-treat (ITT) and per-protocol analysis with proportions compared using chi-square or Fisher’s Exact Test for low cell counts. Results: A total of 134 patients were diagnosed and treated for HP during the study period: 38 in the pre-pharmacy group and 96 in the pharmacist intervention group. In ITT analysis, successful eradication did not differ significantly between groups. Per-protocol analysis revealed significantly higher eradication in the pharmacist group. Antibiotic regimens overall differed between the cohorts with less use of clarithromycin-based triple therapy and greater use of non-bismuth quadruple (concomitant) therapy in the pharmacist group. Other evaluated items were not significantly different between groups. Conclusions: Clinical pharmacist HP care management was associated with more consistent, guideline-concordant antibiotic regimen selection and higher eradication rates among patients completing confirmatory testing. These findings support a role for pharmacist-led HP care for process improvement including regimen selection and eradication testing; prospective studies with systematic confirmatory testing are needed to determine the model’s effect on eradication itself.
- 1 April 2019
- Published by Elsevier in Journal of the National Medical Association
- Vol. 111 (2) , 198-201
Protective Propensity of Race or Environmental Features in the Development of Barrett's Esophagus in African Americans – A Single Center Pilot Study
- 1 April 2019
- Published by Elsevier in Journal of the National Medical Association
- Vol. 111 (2) , 198-201
Protective Propensity of Race or Environmental Features in the Development of Barrett's Esophagus in African Americans – A Single Center Pilot Study
- Open Access
- 11 December 2014
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2014, 1-2
Does Gastrointestinal Dysmotility Predispose to Recurrent or Severe Forms ofClostridium difficileInfections?
Clostridium difficileinfection (CDI) is the most common cause of hospital-acquired diarrhea. A limited number of studies have looked at the risk factors for recurrent CDI. Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE) is a rare multisystemic disorder that causes gastrointestinal dysmotility. Herein we present a patient with MNGIE who suffered recurrent and severeC. difficileinfection despite appropriate treatment. We aim to bring the gastroenterologist’s attention to gastrointestinal dysmotility as a possible risk factor for the development of recurrent or severe forms ofC. difficileinfections.
- 11 December 2014
- Published by Wiley in Case Reports in Gastrointestinal Medicine
- Vol. 2014, 1-2
Open AccessDoes Gastrointestinal Dysmotility Predispose to Recurrent or Severe Forms ofClostridium difficileInfections?
Clostridium difficileinfection (CDI) is the most common cause of hospital-acquired diarrhea. A limited number of studies have looked at the risk factors for recurrent CDI. Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE) is a rare multisystemic disorder that causes gastrointestinal dysmotility. Herein we present a patient with MNGIE who suffered recurrent and severeC. difficileinfection despite appropriate treatment. We aim to bring the gastroenterologist’s attention to gastrointestinal dysmotility as a possible risk factor for the development of recurrent or severe forms ofC. difficileinfections.